新的肺癌治疗组合将患EGFR突变的病人的寿命延长近10个月。 A new lung cancer treatment combo extends life by nearly 10 months for patients with EGFR mutations.

FLAURA2第3阶段试验发现,将基于白金的化疗和微米添加到osimertinib中可以改善受EGFR改造的非小型细胞肺癌患者的总体存活率,包括脑癌、肝癌或骨头转移、特定的EGFR变异、TP53变异或可检测的循环肿瘤DNA患者。 A phase 3 trial, FLAURA2, found that adding platinum-based chemotherapy and pemetrexed to osimertinib improved overall survival in patients with EGFR-mutated non-small cell lung cancer, including those with brain, liver, or bone metastases, specific EGFR mutations, TP53 alterations, or detectable circulating tumor DNA. 总体存活率中位数为47.5个月,结合数为37.6个月,仅Osimertinib就有37.6个月,各分组之间有一致的好处。 Median overall survival was 47.5 months with the combination versus 37.6 months with osimertinib alone, with consistent benefits across subgroups. 这些结果在2025年欧洲紧急和应急管理组织大会上提出,支持将这种结合作为符合资格的病人的新护理标准。 The results, presented at the 2025 ESMO Congress, support the combination as a new standard of care for eligible patients.